Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a
QT-prolonging drug is added to a medication profile that already contains a potential
QT-prolonging drug. An ECG is taken before the administration of the new drug and a week
after starting the new drug to investigate the change in duration of the QTc-interval. Risk
factors for developing QT-prolongation and blood concentrations of potassium and creatinine
are documented.
Details
Lead Sponsor:
Katholieke Universiteit Leuven KU Leuven
Collaborator:
Agentschap voor Innovatie door Wetenschap en Technologie